CN116790754B - Marker combination for prognosis prediction of thyroid undifferentiated carcinoma and application thereof - Google Patents
Marker combination for prognosis prediction of thyroid undifferentiated carcinoma and application thereof Download PDFInfo
- Publication number
- CN116790754B CN116790754B CN202310797030.9A CN202310797030A CN116790754B CN 116790754 B CN116790754 B CN 116790754B CN 202310797030 A CN202310797030 A CN 202310797030A CN 116790754 B CN116790754 B CN 116790754B
- Authority
- CN
- China
- Prior art keywords
- atc
- cells
- tim3
- prognosis
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004393 prognosis Methods 0.000 title claims abstract description 47
- 210000001685 thyroid gland Anatomy 0.000 title claims abstract description 13
- 201000009030 Carcinoma Diseases 0.000 title claims abstract description 12
- 208000010576 undifferentiated carcinoma Diseases 0.000 title claims abstract description 12
- 239000003550 marker Substances 0.000 title abstract description 48
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims abstract description 58
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims abstract description 57
- 210000004027 cell Anatomy 0.000 claims description 92
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 39
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 55
- 230000014509 gene expression Effects 0.000 abstract description 46
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 abstract description 39
- 102000017578 LAG3 Human genes 0.000 abstract description 39
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 abstract description 33
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 abstract description 33
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract description 24
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract description 24
- 238000000034 method Methods 0.000 abstract description 18
- 238000011282 treatment Methods 0.000 abstract description 13
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 abstract description 12
- 102100025136 Macrosialin Human genes 0.000 abstract description 12
- 238000001514 detection method Methods 0.000 abstract description 11
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract description 10
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 abstract description 10
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 abstract description 10
- 238000011156 evaluation Methods 0.000 abstract description 10
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract description 9
- 238000007405 data analysis Methods 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 5
- 238000012163 sequencing technique Methods 0.000 abstract description 5
- 238000003766 bioinformatics method Methods 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 102100026882 Alpha-synuclein Human genes 0.000 abstract 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 abstract 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 abstract 1
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 abstract 1
- 238000012151 immunohistochemical method Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 73
- 108090000623 proteins and genes Proteins 0.000 description 53
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 38
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 38
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 21
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 21
- 230000002055 immunohistochemical effect Effects 0.000 description 19
- -1 PD1 Proteins 0.000 description 15
- 210000002865 immune cell Anatomy 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000012188 paraffin wax Substances 0.000 description 7
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000010191 image analysis Methods 0.000 description 5
- 238000012174 single-cell RNA sequencing Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 2
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
- 101150027068 DEGS1 gene Proteins 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 238000003559 RNA-seq method Methods 0.000 description 2
- 208000033781 Thyroid carcinoma Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 201000008440 thyroid gland anaplastic carcinoma Diseases 0.000 description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 2
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 235000012571 Ficus glomerata Nutrition 0.000 description 1
- 244000153665 Ficus glomerata Species 0.000 description 1
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 description 1
- 101000961156 Homo sapiens Immunoglobulin heavy constant gamma 1 Proteins 0.000 description 1
- 101000840257 Homo sapiens Immunoglobulin kappa constant Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000738413 Homo sapiens T-cell surface glycoprotein CD3 gamma chain Proteins 0.000 description 1
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 description 1
- 102100029572 Immunoglobulin kappa constant Human genes 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 102100037911 T-cell surface glycoprotein CD3 gamma chain Human genes 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000013144 data compression Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 208000012584 pre-descemet corneal dystrophy Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The application provides a marker combination for prognosis prediction of thyroid undifferentiated carcinoma and application thereof, and relates to the technical field of biological medicine and medical detection, wherein the marker combination comprises at least one of CD56, CD68, CD20, TIM3, LAG3, TIGIT, CTLA4 and PD1. The application is based on single cell sequencing and big data analysis, the 8 indexes are obtained through screening, then a model is built through a bioinformatics analysis method, and the expression characteristics of the 8 indexes in thyroid undifferentiated carcinoma tumor tissues are verified through an immunohistochemical method; further, the correlation between the above 8 indices and the prognosis of thyroid undifferentiated carcinoma was clarified by data analysis. The invention has important significance for early evaluation of prognosis of thyroid undifferentiated carcinoma, assisting clinical decision and developing new thyroid undifferentiated carcinoma treatment targets.
Description
Technical Field
The application relates to the technical field of biological medicine and medical detection, in particular to a marker combination for prognosis prediction of thyroid undifferentiated carcinoma and application thereof.
Background
Thyroid undifferentiated carcinoma (anaplastic thyroid carcinoma, ATC), also known as anaplastic thyroid carcinoma, progresses rapidly and has extremely high mortality rate, with more than 50% of thyroid carcinoma death cases being caused by ATC.
Histopathological examination is a gold standard for diagnosis of ATC. Surgical excision is the most commonly used treatment for ATC. In recent years, small molecule targeted drugs such as dasafil, qu Meiti, and PD-L1/PD-1 immunosuppressants have also been used for ATC treatment, but only some patients can obtain expected therapeutic effects, and the rest of patients die within 2 years after various treatments.
At present, biomarkers for ATC prognosis prediction are not available, and effective prompt cannot be given to whether more positive treatment measures should be taken clinically, so that a part of ATC patients with better prognosis can be given up to treat, and a part of ATC cancer patients with poor prognosis receive a large amount of useless treatment, so that the economic burden of families and society is greatly increased. Therefore, there is a need to develop a marker combination for ATC prognosis prediction to enable early assessment of ATC prognosis, and to timely administer specific treatments to patients, thereby improving ATC prognosis and avoiding unnecessary medical expenditure.
Disclosure of Invention
To solve the above problems, the present application provides a marker combination for ATC prognosis prediction and application thereof, which can evaluate the prognosis of ATC early and timely perform specific treatment on a patient, thereby improving ATC prognosis and avoiding unnecessary medical expenditure.
In a first aspect, the present application provides a marker combination for ATC prognosis prediction, the marker combination comprising at least one of CD56, CD68, CD20, TIM3, LAG3, TIGIT, CTLA4, and PD1.
Optionally, the marker combination comprises at least one of CD56, CD20, TIM3, LAG3, PD1, CD3, and CD 8.
In a second aspect, the present application provides the use of a marker combination according to the first aspect for the preparation of a product for predicting ATC prognosis.
Optionally, the prognosis includes determining a treatment regimen and predicting the effectiveness of the treatment regimen, predicting patient survival, and/or assessing the infiltration rate of immune cells in ATC tumor tissue.
In a third aspect, the present application provides a product for predicting ATC prognosis, comprising a product for detecting the expression level of a gene as follows, or a product for detecting the expression level of a protein encoded by a gene as follows, or a product for detecting the expression level of an mRNA transcribed by a gene as follows:
the gene comprises at least one of CD56, CD68, CD20, TIM3, LAG3, TIGIT, CTLA4, and PD 1; preferably, the gene comprises at least one of CD56, CD20, TIM3, LAG3, PD1, CD3 and CD 8.
Alternatively, the product comprises a reagent, kit, chip or other diagnostic tool.
Alternatively, the product is a kit for detecting a protein comprising CD56, CD20, TIM3, LAG3, PD1, CD3, CD 8.
In a fourth aspect, the present application provides the use of a marker combination according to the first aspect for constructing a model for predicting ATC prognosis and/or for constructing a method for predicting ATC prognosis.
In a fifth aspect, the present application provides a method of assessing ATC prognosis, the method comprising the steps of:
step one, detecting the expression of CD56, CD20, TIM3, LAG3, PD1, CD3 and CD8 in ATC tumor tissues by adopting an Immunohistochemical (IHC) technology;
determining the expression quantities of CD56, TIM3, LAG3 and PD1 in ATC tumor tissues by adopting an image analysis technology; and the number of infiltrating T cells (CD 3 positive cells), B cells (CD 20 positive cells), depleted T cells (TIM 3/CD8, LAG3/CD8, PD1/CD8 double positive cells) in tumor tissue;
step three, evaluating an image analysis result; if tumor tissue overexpresses TIM3, CD56, while depleting T cells in increased numbers, this ATC case is considered highly defective in prognosis.
Alternatively, an ATC case is considered highly adverse in prognosis if the proportion of TIM3, CD56 positive cells or TIM3/CD8 double positive depleted T cells in the tumor tissue is > 50%.
Compared with the prior art, the technical scheme provided by the embodiment of the application has the following advantages:
at present, biomarkers for ATC prognosis prediction are not available, and effective prompt cannot be given for whether more positive therapeutic measures should be taken clinically. The embodiment of the application provides a marker combination for ATC prognosis prediction, which is characterized in that firstly, a group of marker combinations are obtained by screening based on single cell sequencing and big data analysis, then a model is built through a bioinformatics analysis method, and the expression characteristics of the group of markers in an ATC tumor tissue are verified through an IHC method; further, the correlation between the marker combination and the ATC prognosis was clarified by data analysis. The invention has important significance for early evaluation of ATC prognosis, assisting clinical decision and developing new ATC treatment targets.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the application and together with the description, serve to explain the principles of the application.
In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings that are required to be used in the description of the embodiments or the prior art will be briefly described below, and it will be obvious to those skilled in the art that other drawings can be obtained from these drawings without inventive effort.
FIG. 1 is a graph showing the ratios of various populations of cells analyzed at the single cell level in ATC, papillary thyroid carcinoma (papillary thyroid carcinoma, PTC) and normal thyroid tissue (normal tyroid, nThtyroid) provided in the examples herein; wherein (a) sample composition, processing, bioinformatics analysis, and IHC validation workflow of the scRNA-seq dataset; (B) UMAP plot visualizes 11 cell clusters; (C) Bubble map of normalized expression level of cell lineage specific marker gene; color depth represents average expression value level, and dot size represents percentage of specific marker gene in each cluster;
FIG. 2 shows the ratio of various immune cells analyzed at the single cell level in thyroid undifferentiated carcinoma, PTC, nThyroid; wherein, (a) a UMAP profile of immune cells in a tissue of class 3; (B) UMAP panels display 12 immune cell clusters; (C) Bubble diagram of standardized expression level of immune cell lineage specific marker gene, color depth represents average expression value level, and dot size represents percentage of specific marker gene in each cluster; (D) representative immune cell cluster duty cycle in each sample;
FIG. 3 is a schematic representation of the CD8+ T cell depletion marker gene expression in ATC, PTC, nThyroid provided in the examples herein; wherein, (a) the UMAP diagram shows 8 cd8+ T cell clusters; each color and number represents a respective cd8+ T cell cluster; (B) Bubble map of normalized expression levels of immune markers and depletion marker genes in cd8+ T cells. Color depth represents average expression value level, and dot size represents percentage of specific marker gene in each cluster; (C) the ratio of each cd8+ T cell cluster in each sample; (D) The expression pattern of cd8+ T cell clusters in class 3 tissues was mainly depleted of marker genes. Three colors represent three classes of tissue; (E) Comparison of expression of major depletion marker genes in group 3 tissues in Bulk RNA-seq dataset (GSE 33630); * P <0.05, < P <0.01, < P <0.001, < P <0.0001; (F) The Kaplan-Meier survival curve shows the difference in total survival between the high and low expression groups of TIM3 (also known as HAVCR 2), LAG3, TIGIT and PD1 (also known as PDCD 1) in ATC cases of GSE76039 dataset. (G) Expression of ENTPD1 in each cd8+ T cell cluster in class 3 tissues; (H) GSVA analysis of differences in the activity of the marker pathways between class 3 tissues; red represents a high degree of enrichment of the signal pathway, and blue represents a low degree of enrichment of the signal pathway;
FIG. 4 shows the expression of CD20, CD3, CD68, CD56 in ATC and PTC tumor tissues in the marker combinations provided in the examples of the present application; wherein (A) is the detection result of single-color IHC of CD20, CD3 and CD 68; (B) is the detection result of multi-color IHC of CD3, CD8 and CD 56; (C) Analysis results (vs PTC, ×p <0.01, ×0.01< P < 0.05) for positive cell ratios of CD20, CD3, CD68, CD8, CD56 in ATC tumor tissues with PTC, total survival (OS) greater than 1year, ATC with OS less than 1 year.
FIG. 5 shows the expression of LAG3, PD1, TIM3, CD8 in ATC and PTC tumor tissues and the survival analysis results of ATC cases in the marker combinations provided in the examples of the present application; wherein (A) is the multicolor IHC detection result of LAG3, PD1, TIM3 and CD 8; (B) Analysis results for positive LAG3, PD1, TIM3, CD8 cells and double positive LAG3/CD8, PD1/CD8, TIM3/CD8 cell ratios in ATC tumor tissues with OS greater than 1year and ATC less than 1year (vs PTC, #0.01, # 0.01<P<0.05;vs ATC OS>1year, #0.01< P < 0.05); (C) Survival curves of ATC patients with a tumor area TIM3 positive cells ratio of greater than or less than 50% show that survival of TIM3 positive cells with a ratio of less than 50% is prolonged by greater than 50%; (D) Survival curves for ATC patients with tumor area TIM3/CD8 double positive cells at ratios greater than or less than 50% showed prolonged survival for those with TMI3/CD8 double positive cells at ratios less than 50% at ratios greater than 50%.
Detailed Description
For the purposes of making the objects, technical solutions and advantages of the embodiments of the present application more clear, the technical solutions of the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application, and it is apparent that the described embodiments are some embodiments of the present application, but not all embodiments. All other embodiments, which can be made by one of ordinary skill in the art without undue burden from the present disclosure, are within the scope of the present application based on the embodiments herein.
Unless specifically indicated otherwise, the various raw materials, reagents, instruments, equipment, and the like used in this application are commercially available or may be prepared by existing methods.
The inventive thinking of this application is:
at present, biomarkers which can be used for the prognosis prediction of ATC are not available, and effective prompt cannot be given for whether more positive treatment measures should be taken clinically, so that a part of ATC cancer patients which can obtain better prognosis after positive treatment are abandoned; meanwhile, a part of ATC patients with poor prognosis receive a large amount of useless treatment, and the economic burden of families and society is greatly increased.
Therefore, there is a need to develop a marker combination for ATC prognosis prediction to enable early assessment of ATC patient prognosis, thereby improving ATC prognosis and avoiding unnecessary medical expenditure.
In order to solve the above problems, the inventive technical idea of the present application includes the following processes:
the present invention systematically compared the cellular component changes between 3 tissues by integrating the single cell sequencing data of ATC, PTC, nThyroid, and identified 11 major cell clusters, including 2 epithelium, 2 stroma, and 7 immune cell clusters, annotated by cell lineage specific marker genes.
The inventors reagglomerate immune cells, including T/NK cells (CD 3D, CD3E, CD3G, CD 247), macrophages (CD 14, FCGR3A, LYZ, S100A8, S100A 9), B cells and plasma cells (CD 79A, CD79B, MS A1, IGKC, IGHG1, MZB 1), and dendritic cells (HLA-DRA, HLA-DRB 1).
The data show that immune cell lineages present different enrichment preferences in class 3 tissues, with T cells (marker gene CD 3) and NK cells (marker gene CD 56) being the largest immune cell clusters, which account for significantly higher ratios in ATC than in other class 2 tissues; macrophages (labeled gene CD 68) are more abundant than nThyroid in ATC and PTC tissues; however, B cells (labeled gene CD 20) are more abundant in nThyroid than ATC and PTC, as opposed to macrophages.
The inventor further analyzes the surface markers of CD8 positive T cells (T cells with killing function) in 3 tissues, and discovers that 5 typical T cell depletion marker genes (including TIM3, LAG3, TIGIT, CTLA4 and PD 1) are remarkably increased in the ATC tissues compared with PTC and nThyroid. To this end, the inventors screened 8 indices of CD56, CD68, CD20, TIM3, LAG3, TIGIT, CTLA4, PD1 together, and speculated that they correlated with the prognosis of ATC.
Then, the invention adopts IHC method to detect ATC and PTC tumor tissue, and carries out correlation analysis to the detection result and OS of the patient. The results show that the survival time of the ATC patient and the number of the infiltrated depleted T cells in the tumor tissues of the ATC patient and the expression amounts of LAG3, TIM3, PD1 and CD56 all show negative correlation trends; furthermore, compared to ATC cases with OS for more than 1year, the CD3 positive cells (T cells) were decreased in ATC case tumor tissues with OS for less than 1year, but the CD68, CD56, TIM3 positive cells and TIM3/CD8, PD1/CD8, LAG3/CD8 double positive cells (depleted T cells) were increased in proportion.
The above results demonstrate that decreased T cells, increased MC cells and depleted T cells in ATC tumor tissue, while increased CD56 expression, are indicative of a high level of ATC prognosis. Meanwhile, the results provide more references for in-depth understanding of the association of tumor immune microenvironment and ATC occurrence and clinical treatment strategies of thyroid undifferentiated carcinoma, and provide ideas for developing new ATC treatment targets.
Accordingly, the present application provides a marker combination for ATC prognosis prediction comprising at least one of CD56, CD68, CD20, TIM3, LAG3, TIGIT, CTLA4 and PD1. Preferably, the marker combination comprises at least one of CD56, CD20, TIM3, LAG3, PD1, CD3 and CD 8.
The application is based on single cell sequencing and big data analysis, and 8 genes of CD56, CD68, CD20, TIM3, LAG3, TIGIT, CTLA4 and PD1 are obtained through screening, so that the gene can be used as a marker combination for ATC prognosis prediction. Preferably, the marker combination comprises at least one of CD56, CD20, TIM3, LAG3, PD1, CD3 and CD 8.
Based on one general inventive concept, the present application provides the use of a marker combination according to the first aspect for the preparation of a product for predicting ATC prognosis.
In some alternative embodiments, the present application provides a product for predicting ATC prognosis, such as a reagent, kit, chip or other diagnostic tool, and the like, preferably a kit for detecting proteins including CD56, CD20, TIM3, LAG3, PD1, CD3, CD8, comprising detecting the expression level of a gene as follows, or detecting the expression level of a protein encoded by a gene as follows, or detecting the expression level of an mRNA transcribed from a gene as follows:
the gene comprises at least one of CD56, CD68, CD20, TIM3, LAG3, TIGIT, CTLA4, and PD 1; preferably, the gene comprises at least one of CD56, CD20, TIM3, LAG3, PD1, CD3 and CD 8.
Based on one general inventive concept, the present application provides the use of a marker combination according to the first aspect for constructing a model for predicting an ATC prognosis and/or for constructing a method for predicting an ATC prognosis.
In some alternative embodiments, the present application provides a method of assessing ATC prognosis, the method comprising the steps of:
step one, detecting CD56, CD20, TIM3, LAG3, PD1, CD3 and CD8 expression in ATC tumor tissues by adopting IHC;
determining the expression quantities of CD56, TIM3, LAG3 and PD1 in ATC tumor tissues by adopting an image analysis technology; and the number of infiltrating T cells (CD 3 positive cells), B cells (CD 20 positive cells), depleted T cells (TIM 3/CD8, LAG3/CD8, PD1/CD8 double positive cells) in tumor tissue;
step three, evaluating an image analysis result; if tumor tissue overexpresses TIM3, CD56, while depleting T cells in increased numbers, this ATC case is considered highly defective in prognosis.
Alternatively, an ATC case is considered highly adverse in prognosis if the proportion of TIM3, CD56 positive cells or TIM3/CD8 double positive depleted T cells in the tumor tissue is > 50%.
The present application is further illustrated below in conjunction with specific examples. It should be understood that these examples are illustrative only of the present application and are not intended to limit the scope of the present application. The experimental procedures, which are not specified in the following examples, are generally determined according to national standards. If the corresponding national standard does not exist, the method is carried out according to the general international standard, the conventional condition or the condition recommended by the manufacturer.
Example 1
The single cell integration map of ATC, PTC, nThyroid was drawn in this example, and the ratio changes of various cells were compared. The specific method comprises the following steps:
1. single cell RNA expression matrices were downloaded from the GEO database of NCBI. The database access address is: https:// www.ncbi.nlm.nih.gov/geo/. The RNA sequencing dataset was retrieved in the GEO database as a search with ((scRNA) OR (single cell RNA) OR (scRNA-seq) OR (single cell RNAsequencing)) AND ((tyroid cancer) OR (thyroidcarcinoma)). Finally, a scRNA-seq dataset from 18 total samples of GEO: GSE184362 and GSE148673 was selected. Of these, 29110 cells were from 6 nttyroid cells, 46926 cells were from 7 PTC tumor tissues, 15565 were from 5 ATC tumor tissues, and 91601 cells in total. The 18 samples were prepared according to the user guidelines of the Single Cell 3' v2 kit of 10 x Genomics.
2. Quality control procedures were performed using the "setup" R software package (v4.1.1), and cells meeting any of the following criteria were filtered: (1) The number of genes observed in the cell (nFeature), i.e., the number <200 or >2500 of non-0 per column in the expression matrix. (2) The amount of gene expression in the cell (nCount), i.e., the sum of the columns in the expression matrix >25000. (3) A cell having a mitochondrial gene expression ratio (percentage. Mt) > 15%.
3. The characteristic expression of each cell was normalized using global-scaling normalization method "lognormal", processed to total expression, and multiplied by a scale factor (default 10,000), and the results were then logarithmically transformed using the normazedata () function in semoat. The normalized expression profiles of all samples were then combined using the merge () function in the R statistical programming language (v3.6.3).
4. Calculation was performed using a semat, and HVG screening was performed to obtain 3000 hypervariable genes.
5. The different data sets are integrated by using the harmony (v0.1.0) to identify the shared cell state existing between the different data sets, and the technical noise influence between the data sets and the cells is eliminated, so that the difference between genes mainly reflects biological heterogeneity, and the downstream analysis task is facilitated. The low-dimensional expression matrix after the batch effect correction of all samples is obtained, and after clustering, other cell groups are formed by cells derived from normal tissues and cells of tumor tissues together except for tumor cell groups, so that the batch effect removal effect is good, and the data can be used for subsequent cell type and molecular difference comparison.
6. PCA is carried out on the expression matrix of the screened high variable characteristic genes, the optimal number of main components are selected, original characteristic information is reserved as much as possible, the dimension of data used in subsequent analysis is reduced, and reasonable data compression is realized.
7. The sequential processing and analysis of the scRNA-seq data is performed using the Seurat package, including unsupervised graph-based clustering and unified manifold approximation and projection (uniform manifold approximation and projection, UMAP) dimension reduction visualization, etc.
8. Map-based unsupervised clustering of cells was performed using FindNeighbors () and FindClusters () functions in semat. The "cluster tree" based visualization method helps to find the best cluster resolution. Individual cells are divided into different cell groups by clustering, so that heterogeneity among cell types is found, and inherent biological rules are mined. FindClusters () function is then applied based on the shared nearest neighbor (shared nearest neighbor, SNN) algorithm to obtain the final clustering result. Finer sub-clusters in the main cell types were obtained by a multi-round clustering process.
9. Using UMAP nonlinear dimension reduction enables data to be visualized in a low-dimensional space.
10. Cell type specific Marker gene sets are constructed by consulting the literature, retrieving the corresponding Marker gene database, screening for Differentially Expressed Genes (DEG). Wherein the DEGs in each cell cluster were identified using findalmarkers () function in semat. The identification standard is as follows: (1) Expressed in more than 20% of cells in either or both groups; (2) |log2fc| >0.5; (3) Wilcoxon rank sum test corrected P <0.01. If the DEGs <10 between two clusters, the clusters are merged. The screened differential genes need to be analyzed one by one, and the current Marker gene verification is combined. If a Marker gene is differentially expressed in a cell cluster, the cell cluster is labeled as the cell type represented by the Marker gene.
11. The function module score of the cell was calculated using the AddModuleScore () function in the setup. The method was used to calculate the average abundance level of the published signature gene list versus the aggregate abundance level of the random control gene set.
12. The Hallmark gene set of the molecular characteristic database is used as a functional gene set of GSVA enrichment analysis, the enrichment difference of the gene sets in cells of different groups is analyzed, and the functional characteristics of the cells of different groups are read.
13. Converting the gene expression matrix into a gene set variation score matrix (comprehensive expression values of all genes in a gene set), obtaining GSVA enrichment scores of all the channels in each cell, judging the enrichment degree of all the channels, and then analyzing by using a limma package to obtain the channels with obvious differences among all the groups.
The results were as follows:
1. as shown in fig. 1, 11 major cell clusters, including 2 epithelium, 2 stroma and 7 immune cell clusters, were identified in total by the system comparing cell composition changes between 3 tissues by integrating single cell sequencing data of ATC, PTC and nThyroid tissues, annotated by cell lineage specific marker genes, according to an embodiment of the present invention.
2. As shown in fig. 2, immune cell lineages exhibit different enrichment preferences in ATC, PTC, and nThyroid tissues, wherein T cells (labeled with CD 3) and NK cells (labeled with CD 56) are the largest immune cell clusters, which account for significantly higher ratios in ATC than in other class 2 tissues, according to an embodiment of the invention; macrophages (labeled gene CD 68) are more abundant in ATC and PTC tissues than the nThyroid tissues; however, B cells (labeled gene CD 20) are more abundant in the nThyroid than ATC and PTC tissues, as opposed to macrophages.
3. As shown in FIG. 3, according to the embodiment of the present invention, there was a difference in the surface markers of CD8 positive T cells (i.e., killer T cells) in ATC, PTC and nThyroid tissues, and it was found that 5 typical T cell depletion marker genes (including TIM3, LAG3, TIGIT, CTLA4, PD 1) were expressed higher in ATC tissues than in PTC and nThyroid tissues.
Example 2
In this example, IHC was used to detect expression of a combination of markers (CD 56, CD20, TIM3, LAG3, PD1, CD3, CD 8) in ATC and PTC tumor tissues and the differences were compared. The specific method comprises the following steps:
1. the positive ATC cases are confirmed by the pathological morphological detection after the group is put into the group, and because the ATC cases are rare, the PTC cases which are equivalent to the ATC cases in gender, age and tumor volume are further put into the group by adopting a one-by-one pairing mode after the ATC cases are put into the group.
2. And taking paraffin embedded tumor tissues remained after clinical pathology detection of the group of cases as samples, and performing conventional paraffin flaking on the samples.
3. HE staining was performed on the paraffin sections of the samples.
4. Samples paraffin sections were subjected to IHC single staining for CD20, CD3, CD8, and IHC multiple staining for CD56, CD8, LAG3, TIM3, PD1.
5. Scanning the slice by adopting a pathological full-slice scanning system; IHC single-staining slices directly generate images, IHC multiple-staining slices generate images with superimposed colors of indexes.
6. The image is evaluated according to the following steps:
step one, a positive signal with any intensity exists in a cell membrane or a cell plasma, and the cell is considered to express an index corresponding to the positive signal.
Step two, analyzing the number of cells with a certain positive signal in all images by adopting Image J software; the duty cycle of a cell is then calculated according to the formula in table 1.
And thirdly, interpreting images by two pathologists, and evaluating the duty ratio of certain cells according to a formula shown in the table 1.
Step four, comparing the average value of the evaluation results of the two doctors with the evaluation result of Image J software to determine the consistency of the evaluation results; and if the two steps are inconsistent, repeating the second step and the third step.
And fifthly, taking the average value of the evaluation results of two doctors as the ratio of certain cells in the image, and gathering data for statistical analysis.
TABLE 1 IHC dyeing index and calculation formula thereof
T T cells, B B cells, MC macrophages, NK natural killer cells, exT depleted T cells.
The results were as follows:
1. the co-administration group ATC (n=8) and PTC (n=8) cases 16.
2. According to an embodiment of the present invention, the expression of the marker combinations (CD 56, CD20, TIM3, LAG3, PD1, CD3, CD 8) in ATC and PTC tumor tissues is shown in fig. 4, 5 and table 2. The results show that the expression level of the index in the ATC tumor tissue is obviously higher than that of the PTC tumor tissue. The results suggest that ATC and PTC tumor cells have different immunophenotype characteristics.
3. The case was considered positive when the positive cells in the tumor tissue accounted for > 10%. IHC staining results show that the positive rates of LAG3, TIM3 and PD1 in the ATC tumor tissues are respectively 100%, 100% and 87.5%, and 25%, 50% and 12.5% in the PTC tumor tissues. In ATC tumor tissue, TIM3 expression was higher than LAG3 and PD1. The result shows that the T cell depletion related index in tumor tissue is highly expressed and is one of the pathological characteristics of ATC.
4.T cells are significantly increased in ATC tumor tissue, wherein T cells expressing CD8 with killing function are also significantly increased in ATC tumor tissue. However, killer T cells in ATC tumor tissue express mostly depletion indicators (LAG 3, TIM3 or PD 1). Wherein the TIM3/CD8 double-positive cells are the most, and the LAG3/CD8 double-positive cells are the next least, and the PD1/CD8 double-positive cells are the least. This result suggests that although T cell infiltration is increased in ATC tumor tissue, most are in a depleted T state, which may be associated with poor ATC prognosis.
CD56 expressed negative in all PTC tumor tissues but positive in 75% of ATC tumor tissues. This result further demonstrates that there is significant biospecificity between ATC and PTC.
TABLE 2IHC staining image analysis results
**vs PTC P<0.01,*vs PTC 0.01<P<0.05,#vs ATC(OS>1year)0.01<P<0.05.
Example 3.
This example evaluates the effect of predicting ATC prognosis by detecting expression of marker combinations (CD 56, CD20, TIM3, LAG3, PD1, CD3, CD 8) in tumor tissue of ATC cases. The specific method comprises the following steps:
1. the ATC cases confirmed by the pathomorphology detection are put into groups, then the residual tumor tissue wax blocks of the put-into-groups cases after the clinical detection are collected, and the clinical information of the gender, age, tumor tissue size, whether metastasis exists, death time and the like of the put-into-groups cases are collected, so that the cases which cannot obtain complete clinical information are removed.
2. And taking paraffin embedded tumor tissues remained after clinical detection of the group of cases as samples, and performing conventional paraffin flaking.
3. Samples of paraffin sections were subjected to IHC single staining for CD20, CD3, CD8, and IHC double staining for CD56/CD68, CD4/CD3, LAG3/CD8, HAVCR2 (also known as TIM 3)/CD 8, PD1/CD 8.
4. Scanning the slice by adopting a pathological full-slice scanning system; IHC single-staining slices directly generate images, IHC multiple-staining slices generate images with superimposed colors of indexes.
5. The image is evaluated according to the following steps:
step one, a positive signal with any intensity exists in a cell membrane or a cell plasma, and the cell is considered to express an index corresponding to the positive signal.
Step two, analyzing the number of cells with a certain positive signal in all images by adopting Image J software; the duty cycle of a cell is then calculated according to the formula in table 1.
And thirdly, interpreting images by two pathologists, and evaluating the duty ratio of certain cells according to a formula shown in the table 1.
Step four, comparing the average value of the evaluation results of the two doctors with the evaluation result of Image J software to determine the consistency of the evaluation results; and if the two steps are inconsistent, repeating the second step and the third step.
And fifthly, taking the average value of the evaluation results of two doctors as the ratio of certain cells in the image, and gathering data for statistical analysis.
6. The cell ratios of the various types in the tissue were calculated by the formula (shown in table 1).
7. The ATC cases in the group are divided into two groups with the OS less than 1year and the OS greater than 1year according to the OS, and the difference of the proportion of various cells in the tumor tissues of the ATC cases in the two groups is compared.
8. The correlation of the cell ratios of the various classes with the OS of the ATC patients in the group was analyzed.
The results were as follows:
1. the total group has complete clinical information and 8 ATC cases with definite death time.
The number of ExT cells infiltrated in tumor tissues of the ATC patient OS and the expression amounts of LAG3, TIM3, PD1 and CD56 all show negative correlation trend.
3. The CD3 positive cells (T cells) were decreased in tumor tissues of ATC cases with OS less than 1year, but the CD68, CD56, TIM3 positive cells and TIM3/CD8, PD1/CD8, LAG3/CD8 double positive cells (depleted T cells) were increased compared to ATC cases with OS for more than 1 year.
4. The result shows that ExT quantity and related specific marker expression quantity in tumor tissues are related to the ATC lifetime.
5. When the proportion of TIM3, CD56 positive cells or TIM3/CD8 double positive depleted T cells in ATC tumor tissue is >50%, the prognosis for this ATC case is highly poor, and the survival is usually less than 1year after such cases are positively treated.
Various embodiments of the present application may exist in a range format; it should be understood that the description in a range format is merely for convenience and brevity and should not be interpreted as a rigid limitation on the scope of the application. It is therefore to be understood that the range description has specifically disclosed all possible sub-ranges and individual values within that range. For example, it should be considered that a description of a range from 1 to 6 has specifically disclosed sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as single numbers within the range, such as 1, 2, 3, 4, 5, and 6, wherever applicable. In addition, whenever a numerical range is referred to herein, it is meant to include any reference number (fractional or integer) within the indicated range.
In this application, unless otherwise indicated, terms of orientation such as "upper" and "lower" are used specifically to refer to the orientation of the drawing in the figures. In addition, in the description of the present application, the terms "include", "comprise", "comprising" and the like mean "including but not limited to". Relational terms such as "first" and "second", and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Herein, "and/or" describing an association relationship of an association object means that there may be three relationships, for example, a and/or B, may mean: a alone, a and B together, and B alone. Wherein A, B may be singular or plural. Herein, "at least one" means one or more, and "a plurality" means two or more. "at least one", "at least one" or the like refer to any combination of these items, including any combination of single item(s) or plural items(s). For example, "at least one (individual) of a, b, or c," or "at least one (individual) of a, b, and c," may each represent: a, b, c, a-b (i.e., a and b), a-c, b-c, or a-b-c, wherein a, b, c may be single or multiple, respectively.
The foregoing is merely a specific embodiment of the application to enable one skilled in the art to understand or practice the application. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the application. Thus, the present application is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (1)
1. Use of a reagent for the preparation of a product for predicting prognosis of thyroid undifferentiated carcinoma, characterized in that the reagent is a depleted T cell duty cycle for detecting TIM3/CD8 double positivity; the ratio of the T cells which are exhausted and have the double positive TIM3/CD8 is the percentage obtained by dividing the total positive cell number of the four indexes of TIM3, CD8, CD3 and DAPI by the total positive cell number of the two indexes of TIM3, CD8, CD3 and DAPI as a denominator.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310797030.9A CN116790754B (en) | 2023-06-30 | 2023-06-30 | Marker combination for prognosis prediction of thyroid undifferentiated carcinoma and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310797030.9A CN116790754B (en) | 2023-06-30 | 2023-06-30 | Marker combination for prognosis prediction of thyroid undifferentiated carcinoma and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116790754A CN116790754A (en) | 2023-09-22 |
CN116790754B true CN116790754B (en) | 2024-02-27 |
Family
ID=88045863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310797030.9A Active CN116790754B (en) | 2023-06-30 | 2023-06-30 | Marker combination for prognosis prediction of thyroid undifferentiated carcinoma and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116790754B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111465613A (en) * | 2017-11-07 | 2020-07-28 | X4 制药有限公司 | Cancer biomarkers and methods of use thereof |
CN115631857A (en) * | 2022-04-01 | 2023-01-20 | 洛兮医疗科技(杭州)有限公司 | Thyroid cancer CD8+ T cell immune related gene prognosis prediction model |
-
2023
- 2023-06-30 CN CN202310797030.9A patent/CN116790754B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111465613A (en) * | 2017-11-07 | 2020-07-28 | X4 制药有限公司 | Cancer biomarkers and methods of use thereof |
CN115631857A (en) * | 2022-04-01 | 2023-01-20 | 洛兮医疗科技(杭州)有限公司 | Thyroid cancer CD8+ T cell immune related gene prognosis prediction model |
Non-Patent Citations (2)
Title |
---|
Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma;Luo Yi等;《Frontiers in Endocrinology》;第13卷;摘要 * |
甲状腺未分化癌的分子机制研究;青晓艳等;《山东大学耳鼻喉眼学报》;第34卷(第3期);第26-31页 * |
Also Published As
Publication number | Publication date |
---|---|
CN116790754A (en) | 2023-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yuan et al. | Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling | |
AU2019277698A1 (en) | Convolutional neural network systems and methods for data classification | |
Milanez-Almeida et al. | Cancer prognosis with shallow tumor RNA sequencing | |
Tran et al. | Inferring causal genomic alterations in breast cancer using gene expression data | |
Fan et al. | HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline | |
Liao et al. | Machine‐learning based radiogenomics analysis of MRI features and metagenes in glioblastoma multiforme patients with different survival time | |
US20140040264A1 (en) | Method for estimation of information flow in biological networks | |
Caines et al. | Cluster analysis of multiplex ligation-dependent probe amplification data in choroidal melanoma | |
CN108884494A (en) | The unicellular Genome Atlas of circulating tumor cell is analyzed to characterize disease heterogeneity in metastatic disease | |
Wallace et al. | Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas | |
CN111164700A (en) | Immuno-oncology applications using next generation sequencing | |
Feng et al. | Spatial analysis with SPIAT and spaSim to characterize and simulate tissue microenvironments | |
Cheng et al. | Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation | |
Farah et al. | Lichenoid dysplasia is not a distinct pathological entity | |
WO2023137433A2 (en) | Methods and systems for determining leukemia or lymphoma levels using lymphoid images | |
WO2023006843A1 (en) | Prediction of brcaness/homologous recombination deficiency of breast tumors on digitalized slides | |
Xia et al. | DNA methylation-based classification of small B-cell lymphomas: a proof-of-principle study | |
CN116790754B (en) | Marker combination for prognosis prediction of thyroid undifferentiated carcinoma and application thereof | |
Jørgensen et al. | Untangling the intracellular signalling network in cancer—A strategy for data integration in acute myeloid leukaemia | |
Wrobel et al. | Statistical analysis of multiplex immunofluorescence and immunohistochemistry imaging data | |
CN114022472B (en) | Tumor infiltrating lymphocyte analysis method, device and storage medium | |
CN105624276B (en) | Endometrioid adenocarcinoma prognosis-related gene and albumen and its application | |
Mar et al. | Model-based clustering in gene expression microarrays: an application to breast cancer data | |
EP3635138B1 (en) | Method for analysing cell-free nucleic acids | |
CN115472294B (en) | Model for predicting transformation speed of small cell transformation lung adenocarcinoma patient and construction method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |